Therefore, it would be of interest to evaluate p300 inhibitors as therapeutic targets against T-ALL, especially those with underlying activating NOTCH1 mutations that display BRD4-dependency. This evidence concerns the gene BRD4 and acute lymphoblastic leukemia.